Enhancing Internal Medicine Resident Competency in Diabetes Care: Comparing Experience-Based and Traditional Continuous Glucose Monitoring Curricula

Enhancing Internal Medicine Resident Competency in Diabetes Care: Comparing Experience-Based and Traditional Continuous Glucose Monitoring Curricula

Experience-based continuous glucose monitoring (CGM) curricula significantly improve internal medicine residents' confidence in applied patient care skills compared to traditional approaches, supporting hands-on CGM training integration in residency programs.
Diminished Arginine Bioavailability in A-β+ Ketosis-Prone Diabetes: A Distinct Metabolic Signature Underlying Ketoacidosis Risk

Diminished Arginine Bioavailability in A-β+ Ketosis-Prone Diabetes: A Distinct Metabolic Signature Underlying Ketoacidosis Risk

This study reveals that reduced arginine availability during hyperglycaemia distinguishes A-β+ ketosis-prone diabetes from type 2 diabetes, implicating impaired arginine metabolism in ketoacidosis pathogenesis and highlighting citrulline supplementation as a potential therapeutic strategy.
Levothyroxine Treatment and Cardiometabolic Biomarkers in Older Adults with Subclinical Hypothyroidism: A Comprehensive Review

Levothyroxine Treatment and Cardiometabolic Biomarkers in Older Adults with Subclinical Hypothyroidism: A Comprehensive Review

Levothyroxine treatment in older adults with subclinical hypothyroidism shows limited impact on cardiometabolic biomarkers overall but may benefit those with higher TSH levels, highlighting nuanced treatment implications and the need for tailored therapeutic strategies.
Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances

Once-weekly IcoSema versus Daily Insulin Glargine U100 in Type 2 Diabetes: Evidence from the COMBINE 4 Phase 3b Trial and Related Advances

COMBINE 4 demonstrated that once-weekly IcoSema (icodec+semaglutide) offers superior glycemic control, weight reduction, and reduced hypoglycemia versus daily insulin glargine U100 in insulin-naive type 2 diabetes patients, supported by complementary phase 3 studies on insulin icodec.